

Fiscal Note

State of Alaska
2014 Legislative Session

Bill Version: CSSB 173(JUD)
Fiscal Note Number: 3
(S) Publish Date: 3/14/14

Identifier: SB173CS(JUD)-DOA-OPA-02-28-14
Title: SYNTHETIC DRUGS
Sponsor: MEYER
Requester: Senate Judiciary

Department: Department of Administration
Appropriation: Legal and Advocacy Services
Allocation: Office of Public Advocacy
OMB Component Number: 43

Expenditures/Revenues

Note: Amounts do not include inflation unless otherwise noted below. (Thousands of Dollars)

	FY2015 Appropriation Requested	Included in Governor's FY2015 Request	Out-Year Cost Estimates					
			FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020
OPERATING EXPENDITURES								
Personal Services	***		***	***	***	***	***	***
Travel								
Services								
Commodities								
Capital Outlay								
Grants & Benefits								
Miscellaneous								
Total Operating	***	0.0	***	***	***	***	***	***

Fund Source (Operating Only)

None								
Total	***	0.0	***	***	***	***	***	***

Positions

Full-time								
Part-time								
Temporary								

Change in Revenues								
---------------------------	--	--	--	--	--	--	--	--

Estimated SUPPLEMENTAL (FY2014) cost: 0.0 *(separate supplemental appropriation required)*
(discuss reasons and fund source(s) in analysis section)

Estimated CAPITAL (FY2015) cost: 0.0 *(separate capital appropriation required)*
(discuss reasons and fund source(s) in analysis section)

ASSOCIATED REGULATIONS

Does the bill direct, or will the bill result in, regulation changes adopted by your agency? No
If yes, by what date are the regulations to be adopted, amended or repealed?

Why this fiscal note differs from previous version:

Initial Version

Prepared By:	Richard Allen, Director	Phone:	(907)269-3504
Division:	Office of Public Advocacy	Date:	02/28/2014 06:10 PM
Approved By:	Curtis Thayer, Commissioner	Date:	02/28/14
Agency:	Department of Administration		

FISCAL NOTE ANALYSIS #3

**STATE OF ALASKA
2014 LEGISLATIVE SESSION**

BILL NO. CSSB 173(JUD)

Analysis

SB173 adds a new chapter to AS 17 criminalizing the display, advertising or sale of substances defined by the chapter as "illicit synthetic substances."

The parameters for identifying a substance as an "illicit synthetic drug" are overly broad and may inadvertently include criminalizing the sale of some herbal remedies and other innocuous substances.

The Office of Public Advocacy cannot accurately predict the fiscal impact of this legislation and therefore submits an indeterminate fiscal note.